MADISON, Wis. & NEW YORK & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Cell Line Genetics, Inc., a leader in Stem Cell Quality Assurance services and products, and Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announced today an exclusive agreement under which Cell Line Genetics will sell the Ambry StemArray™ aCGH (array Comparative Genomic Hybridization) product and related services to its current customers as well as other companies and research institutions. Both companies believe this partnership will dramatically expand the availability of the Ambry StemArray and hasten its adoption in the stem cell and regenerative medicine market globally.
